Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Fluid Administration and Lymphedema Risk in Breast Cancer Patients
NCT06672224Withdrawn
- Sponsor
- City of Hope
- Start
- Aug 2025
- Primary completion
- Aug 2026
01
Overview
Open-label, single-arm trial, sponsored by City of Hope. Primary endpoint: Percentage of patients with worsening lymphedema in the affected arm at 12 months. Planned start Aug 2025; status: withdrawn.
Beyond the preview
Go deeper on NCT06672224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06672224.